Organisation: Vertex Pharmaceuticals

IAM’s Market Makers of 2023

Via Licensing Alliance’s Heath Hoglund takes the top spot in our annual ranking of the patent market’s most innovative and influential deal makers and decision takers

14 March 2024

Crystal balls at the ready: IAM’s editorial team predicts the year’s biggest stories

Saturday Opinion: We’re back, putting our necks and reputations on the line, and looking ahead to what 2024 will deliver for patent professionals

03 February 2024

Five stories that made 2023 a momentous year for life sciences IP

The dawn of a new era for CRISPR patent strategy, multiplying mRNA patent wars, and 10x Genomics and NanoString’s cross-border spat were among the developments that defined the last 12 months

02 January 2024

Editas licenses CRISPR patents to Vertex in $100 million-plus deal

The speedy agreement prevents litigation between the two parties, but other Cas9 disputes may be on the cards

14 December 2023

First US CRISPR Cas9 approval marks start of new era of patent wars

Friday’s green light from the FDA is watershed for IP strategy in the field

11 December 2023

Historic CRISPR drug approval heralds new era in Cas9 IP wars

Green light for first ever Cas9 therapy ushers in next phase of licensing and litigation efforts.

17 November 2023

CRISPR-Cas9 drugmakers like Vertex should come to the table early, says ToolGen’s IP chief

Chief Legal Officer Yoori Kim argues that current patent uncertainty should fuel rather than thwart licensing deals

01 November 2023

Novartis Entresto lawsuit underlines growing importance of cocrystals for patent strategy

US university litigation seeks damages and ongoing royalties over blockbuster heart failure drug which generated $2.22 billion in 2H 2022

13 September 2022

Forma Therapeutics $1.1 billion buyout shows high demand for orphan drug IP

Patent-backed rare disease innovations secure more M&A/licensing investment than any pharma assets outside oncology

07 September 2022

How platform technologies are reshaping life sciences IP value creation

Versatile biotechnologies are changing patterns of collaboration among healthcare innovators

10 February 2022